Back to results
US 8,119,355 B2Granted
Biomarkers for cancer sensitivity and uses thereof
AssigneeThe UAB Research Foundation
InventorsRobert P. Kimberly, Tong Zhou, Takeshi Isoyama
Life of this patent
Estimating the term…
Abstract
Disclosed herein are biomarkers and uses thereof for evaluating anti-cancer efficacy and sensitivity.
Claims9
A method of predicting sensitivity of a cancer cell to a first anti-cancer agent comprising:
- (a) contacting the cancer cell with an effective amount of the anti-cancer agent, wherein the anti-cancer agent comprises TRA-8 or an antibody having the same epitope specificity as TRA-8;
- and
- (b) evaluating the release by the cell of one or more biomarkers selected from the group consisting of fructose-bisphosphate aldolase A (ALDOA), phosphoglycerate kinase 1 (PGK1), peroxiredoxin 1 (PRDX1), and colfilin 1 (COF1), an increase in release by the contacted cell compared to a control cell indicating that the cancer cell is sensitive to the agent.
A method of determining an effective dose for an anti-cancer agent comprising:
- (a) contacting one or more cancer cells with a plurality of dosages of the anti-cancer agent under conditions that allow cellular release of one or more biomarkers selected from the group consisting of fructose-bisphosphate aldolase A (ALDOA), phosphoglycerate kinase 1 (PGK1), peroxiredoxin 1 (PRDX1), and colfilin 1 (COF1), and histone H4, wherein the anti-cancer agent comprises TRA-8 or an antibody having the same epitope specificity as TRA-8;
- and
- (b) detecting the release at each dosage, higher release rates indicating an effective dosage.
Dependencies are inferred from the claim text.